Company news

Amylyx Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America

April 19, 2023

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome

April 12, 2023

Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

March 12, 2023

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

March 6, 2023

Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

February 6, 2023

Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS

February 1, 2023

Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference

November 21, 2022

Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 9, 2022

Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022

November 2, 2022

Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

October 10, 2022

Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

October 5, 2022

Amylyx Pharmaceuticals Announces Launch of Public Offering

October 3, 2022

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS

September 28, 2022

Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries

September 13, 2022

Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds

September 11, 2022

Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS

September 6, 2022

Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035

September 1, 2022

Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 10, 2022

Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022

August 2, 2022

Amylyx Pharmaceuticals Announces ALBRIOZA™ is Now Available in Canada for the Treatment of ALS

July 28, 2022

Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases

July 17, 2022

Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases

July 5, 2022

Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022

July 4, 2022

Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS

June 12, 2022

Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS

June 2, 2022

Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting

May 25, 2022

Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization

May 15, 2022

Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results

May 11, 2022

Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS

May 4, 2022

Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting

April 1, 2022

Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results

March 29, 2022

Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS

March 29, 2022

Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035

March 27, 2022

Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035

March 17, 2022

Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS

February 24, 2022

Amylyx Pharmaceuticals Expands Executive Team with Appointment of Gina M. Mazzariello as Chief Legal Officer and General Counsel

February 22, 2022

Amylyx Pharmaceuticals Announces FDA Advisory Committee Meeting to Review New Drug Application for AMX0035 for the Treatment of ALS Scheduled for March 30, 2022

February 15, 2022

Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 9, 2022

The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals Partner on Real-World Evidence Generation for a Novel Investigational Therapy in ALS with the Goal of Advancing Health Outcomes for Canadians Living with ALS

February 2, 2022

← Newer news releases

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.